TY - JOUR
T1 - Targeting β-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells
AU - Tang, Weigang
AU - Li, Ying
AU - Yu, Duonan
AU - Thomas-Tikhonenko, Andrei
AU - Spiegelman, Vladimir S.
AU - Fuchs, Serge Y.
PY - 2005/3/1
Y1 - 2005/3/1
N2 - β-Transducin repeat-containing proteins (β-TrCP) serve as substrate recognition component of E3 ubiquitin ligases that control stability of important regulators of cell cycle and signal transduction. β-TrCP function is essential for the induction of nuclear factor κB transcriptional activities, which play a key role in proliferation and survival of cancer cells and are often constitutively up-regulated in human breast cancers. Here we show that inhibition of β-TrCP either by RNAi approach or by forced expression of a dominant-negative β-TrCP mutant suppresses growth and survival of human breast cancer cells. In addition, inhibition of β-TrCP augments the antiproliferative effects of anticancer drugs such as doxorubicin, tamoxifen, and paclitaxel on human mammary tumor cells. These data provide the proof of principle that targeting β-TrCP might be beneficial for anticancer therapies.
AB - β-Transducin repeat-containing proteins (β-TrCP) serve as substrate recognition component of E3 ubiquitin ligases that control stability of important regulators of cell cycle and signal transduction. β-TrCP function is essential for the induction of nuclear factor κB transcriptional activities, which play a key role in proliferation and survival of cancer cells and are often constitutively up-regulated in human breast cancers. Here we show that inhibition of β-TrCP either by RNAi approach or by forced expression of a dominant-negative β-TrCP mutant suppresses growth and survival of human breast cancer cells. In addition, inhibition of β-TrCP augments the antiproliferative effects of anticancer drugs such as doxorubicin, tamoxifen, and paclitaxel on human mammary tumor cells. These data provide the proof of principle that targeting β-TrCP might be beneficial for anticancer therapies.
UR - http://www.scopus.com/inward/record.url?scp=16444372422&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=16444372422&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-04-2597
DO - 10.1158/0008-5472.CAN-04-2597
M3 - Article
C2 - 15753389
AN - SCOPUS:16444372422
SN - 0008-5472
VL - 65
SP - 1904
EP - 1908
JO - Cancer Research
JF - Cancer Research
IS - 5
ER -